Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2006
Laboratory monitoring in oncology.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Duong Cathy D, Loh Jin-Yew
Аннотация
OBJECTIVES: To educate pharmacists about the application of laboratory values in oncology.
METHODS: Research on drugs used in cancer therapy was conducted using multiple sources, including primary, secondary and tertiary references. Online searches were conducted on Medline (1966-2004), EMBASE (1996-2004) and Ovid databases, using a drug's generic name and key words, such as 'adverse effects', 'hematotoxicity', 'renal toxicity', 'hepatotoxicity', 'cardiotoxicity', 'organ dysfunction', and terms describing chemotherapy-related toxicity, such as 'tumour lysis syndrome'.
RESULTS: Laboratory monitoring in oncology was separated into the hematologic, hepatic, renal, cardiovascular and pulmonary systems. Laboratory tests applicable to each system are discussed. In addition, tests pertaining to specific drugs used in cancer therapy are explained. This information was compiled into a comprehensive continuing pharmacy education module.
CONCLUSION: Laboratory monitoring assists the pharmacist in the monitoring of chemotherapy. A general understanding of common tests used in cancer therapy and knowledge specific to drugs used can help the pharmacist tailor drug therapy monitoring.
METHODS: Research on drugs used in cancer therapy was conducted using multiple sources, including primary, secondary and tertiary references. Online searches were conducted on Medline (1966-2004), EMBASE (1996-2004) and Ovid databases, using a drug's generic name and key words, such as 'adverse effects', 'hematotoxicity', 'renal toxicity', 'hepatotoxicity', 'cardiotoxicity', 'organ dysfunction', and terms describing chemotherapy-related toxicity, such as 'tumour lysis syndrome'.
RESULTS: Laboratory monitoring in oncology was separated into the hematologic, hepatic, renal, cardiovascular and pulmonary systems. Laboratory tests applicable to each system are discussed. In addition, tests pertaining to specific drugs used in cancer therapy are explained. This information was compiled into a comprehensive continuing pharmacy education module.
CONCLUSION: Laboratory monitoring assists the pharmacist in the monitoring of chemotherapy. A general understanding of common tests used in cancer therapy and knowledge specific to drugs used can help the pharmacist tailor drug therapy monitoring.